← Eichor
Study identifier: NCT06639828 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Phase 4 Paediatric Study to Evaluate Sonazoid Safety and Efficacy for Contrast-Enhanced Ultrasound Liver Imaging

Condition: Focal Liver Lesions  ·  Sponsor: GE Healthcare

PhasePhase 4
Planned participants50
Who can joinAll sexes, N/A to 18 Years
Healthy volunteersNo

About this study

Liver tumours, 40% of which are benign, account for 1% to 4% of all solid tumours in children. The benign tumours are mainly haemangiomas, liver hamartomas, and liver cell adenomas. The malignant tumours are mainly hepatoblastoma, hepatocellular carcinoma (HCC), malignant liver mesothelioma, and rhabdomyosarcoma. The differential diagnosis of liver masses in children is generally based on the child's age, the clinical evaluation (including alpha-fetoprotein test results), and imaging characteristics. Liver tumours seldom produce clear symptoms and signs in the early stages, and they progress rapidly. As a result, most liver tumours are not diagnosed until the middle or late stages. To improve survival among patients with liver tumours, clinicians must find the liver tumours as early as possible and determine whether the tumours are benign or malignant. Conventional ultrasonography is commonly used for screening, and is preferred as the first-line imaging technique for children. Not only does it have a wide range of applications and a high diagnostic yield, but it is well accepted by patients and their parents. It can be performed in the examination room with the parents present, allowing real-time imaging and direct interaction with patient and parents. CEUS is a non-invasive imaging technology that can continuously and dynamically observe blood perfusion in tumours in real-time through injection of a contrast agent to enhance the blood flow reflux signal in the human body.…

This description comes directly from the study's public registry record.

Talk to the study team

Tingting Wang  ·  +86 21 3895 4500  ·  Tingting.Wang12@gehealthcare.com

David Thompson  ·  +44 (0) 7385 117614  ·  david.thompson1@gehealthcare.com

Always discuss trial participation with your own doctor first.

Locations (6)

Munich University HospitalMünchen, GermanyNot Yet Recruiting
Papa Giovanni XXIII HospitalBergamo, ItalyNot Yet Recruiting
Giannina Gaslini InstituteGenoa, ItalyNot Yet Recruiting
University Hospitals Bristol and Weston NHS Foundation TrustBristol, United KingdomRecruiting
King's College Hospital NHS Foundation TrustLondon, United KingdomRecruiting
Imperial College Healthcare NHS TrustLondon, United KingdomRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06639828